Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Unaudited Preliminary Results Announcement)
Reporting Period: Year ended 31 December 2016 and Quarter ended 31 December 2016
Issued: 8 February 2017
GSK reported continued momentum in 2016, driven by broadly-based sales growth across its three core businesses: Pharmaceuticals, Vaccines, and Consumer Healthcare. The results reflect the full-year impact of the Novartis transaction (completed March 2015) and the exclusion of the former Oncology business. The company highlighted strong new product momentum, improved cash flow, and significant pipeline progression.
Key Financial Metrics
| Metric | 2016 Full Year (£m) | 2016 Growth (CER%) | Q4 2016 (£m) | Q4 2016 Growth (CER%) |
|---|---|---|---|---|
| Turnover | 27,889 | 6% | 7,586 | 3% |
| Core Operating Profit | 7,771 | 14% | 2,062 | 16% |
| Core Operating Margin | 27.9% | - | 27.2% | - |
| Core EPS | 102.4p | 12% | 26.1p | 11% |
| Total EPS | 18.8p | (99%) | 5.3p | >100% |
| Net Cash Flow from Operations | 6,497 | - | 2,991 | - |
| Free Cash Flow | 3,087 | - | 1,768 | - |
| Net Debt | 13,804 | - | 13,804 | - |
Note: CER = Constant Exchange Rate. Total EPS decline is primarily due to the one-off gain from the Oncology disposal in 2015.
Material Changes vs. Prior Period
- Revenue Growth: Group sales grew 6% CER to £27.9 billion. Pharmaceuticals grew 3% CER, Vaccines grew 14% CER, and Consumer Healthcare grew 9% CER. New product sales more than doubled to £4.5 billion.
- Profitability: Core operating profit margin improved to 27.9% (up 3.9 percentage points from 2015) due to operating leverage and cost savings of £1.4 billion delivered in 2016.
- Total Results Volatility: Total operating profit fell 86% to £2.6 billion and Total EPS fell 99% to 18.8p. This was driven by a £9.2 billion profit from the Oncology disposal in 2015 and significant non-core charges in 2016 related to the re-measurement of contingent consideration and put options (ViiV Healthcare and Consumer Healthcare).
- Cash Flow: Net cash flow from operations improved significantly to £6.5 billion (2015: £2.6 billion), reflecting improved operating performance and exchange rate benefits.
- Debt: Net debt increased to £13.8 billion from £10.7 billion, primarily due to a £2.2 billion adverse exchange impact and dividends paid (£4.9 billion), partially offset by free cash flow.
Guidance, Outlook, and Risks
2017 Guidance
Guidance for 2017 core EPS growth is contingent on the timing and impact of generic competition to Advair in the US:
- Scenario A (No Generic): If no generic competitor is introduced, GSK expects 2017 core EPS growth of 5-7% CER.
- Scenario B (Mid-Year Generic): If a substitutable generic is introduced mid-year, GSK expects full-year US Advair sales of ~£1 billion, resulting in core EPS that is flat to a slight decline at CER.
Dividends
A total dividend of 80p was paid for 2016. The company expects to pay an annual ordinary dividend of 80p for 2017.
Risks and Contingencies
- Generic Competition: Significant uncertainty regarding the launch of generic Advair in the US, which could materially impact respiratory sales and earnings.
- Transaction-Related Liabilities: Volatility in total results due to re-measurement of liabilities for contingent consideration and put options associated with ViiV Healthcare and the Consumer Healthcare Joint Venture. In Q4 2016, GSK and Shionogi agreed to remove the Shionogi put option, de-recognizing a £1.2 billion liability to equity.
- Legal Matters: Ongoing litigation and government investigations, though no significant developments were reported since Q3 2016.
Investor Verification Checklist
- Advair Exposure: Verify the specific timeline and market share impact of potential generic Advair entry in the US, as this is the primary variable in 2017 earnings guidance.
- Core vs. Total Reconciliation: Review the reconciliation of Total to Core results to understand the magnitude of non-cash transaction-related charges (£3.9 billion in 2016) impacting reported GAAP earnings.
- Put Option Liabilities: Confirm the status of remaining put options (Pfizer) and contingent consideration liabilities, as exchange rate fluctuations significantly impact their valuation.
- New Product Mix: Assess the sustainability of growth from new products (HIV: Tivicay, Triumeq; Respiratory: Breo, Nucala; Vaccines: Bexsero), which now represent 24% of Pharmaceutical sales.
- Net Debt Trajectory: Monitor the impact of exchange rates on net debt and the company's ability to service debt while maintaining the 80p dividend policy.